Editas Medicine, Inc. (EDIT)
Data as of , from SEC Form 4 filings.
See up to 3 months of EDIT. The 7-day demo opens the 1M and 3M ranges and puts EDIT on your watchlist.
Start 7-day demoLatest EDIT insider trades
About Editas Medicine, Inc. (EDIT)
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
- CAMBRIDGE, MA
- 87
- 2016
- XNAS
EDIT Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 5 | 11,892 | $34K |
| Grant or award | 2 | 1,053,400 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
EDIT insider transactions (Form 4)
3030 Form 4 filings on record, the earliest from Dec 5, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Daniel Scott Ory - Officer | Grant or award | Stock Option (right to buy) | 950,000 | $0.00 | - | |
| Linda Burkly - Officer | Open-market sale | Common Stock | 709 | $3.04 footnote F2 | $2K | |
| ||||||
| Amy Parison - Officer | Open-market sale | Common Stock | 453 | $3.04 | $1K | |
| Gilmore Neil O'Neill - Officer | Open-market sale | Common Stock | 5,124 | $3.04 footnote F2 | $16K | |
| ||||||
| Patrick Thomas Ellinor II - Director | Grant or award | Stock Option (right to buy) | 103,400 | $0.00 | - | |
| Amy Parison - Officer | Open-market sale | Common Stock | 678 | $2.58 | $2K | |
| Linda Burkly - Officer | Open-market sale | Common Stock | 4,928 | $2.67 | $13K | |
| Bernadette Connaughton - Director | Grant or award | Stock Option (right to buy) | 51,700 | $0.00 | - | |
 Jessica Hopfield - Director | Grant or award | Stock Option (right to buy) | 51,700 | $0.00 | - | |
| Andrew Hirsch - Director | Grant or award | Stock Option (right to buy) | 51,700 | $0.00 | - | |
| David Scadden - Director | Grant or award | Stock Option (right to buy) | 51,700 | $0.00 | - | |
| Elliott M. Levy - Director | Grant or award | Stock Option (right to buy) | 51,700 | $0.00 | - | |
| Amy Parison - Officer | Open-market sale | Common Stock | 464 | $2.70 footnote F2 | $1K | |
| ||||||
| Gilmore Neil O'Neill - Officer | Open-market sale | Common Stock | 15,380 | $2.70 footnote F2 | $42K | |
| ||||||
| Linda Burkly - Officer | Open-market sale | Common Stock | 731 | $2.70 footnote F2 | $2K | |
| ||||||
| Gilmore Neil O'Neill - Officer | Grant or award | Stock Option (right to buy) | 1,015,200 | $0.00 | - | |
| Amy Parison - Officer | Grant or award | Stock Option (right to buy) | 292,856 | $0.00 | - | |
| Linda Burkly - Officer | Grant or award | Stock Option (right to buy) | 292,856 | $0.00 | - | |
| Gilmore Neil O'Neill - Officer | Open-market sale | Common Stock | 5,394 | $2.02 footnote F2 | $11K | |
| ||||||
| Amy Parison - Officer | Open-market sale | Common Stock | 474 | $2.02 footnote F2 | $957 | |
| ||||||
| Linda Burkly - Officer | Open-market sale | Common Stock | 749 | $2.02 footnote F2 | $2K | |
| ||||||
| Gilmore Neil O'Neill - Officer | Open-market sale | Common Stock | 5,603 | $2.15 | $12K | |
| Amy Parison - Officer | Open-market sale | Common Stock | 461 | $2.15 | $993 | |
| Linda Burkly - Officer | Open-market sale | Common Stock | 710 | $2.60 | $2K | |
| Amy Parison - Officer | Open-market sale | Common Stock | 458 | $2.60 | $1K | |
| Gilmore Neil O'Neill - Officer | Open-market sale | Common Stock | 5,592 | $2.60 | $15K | |
| Amy Parison - Officer | Open-market sale | Common Stock | 679 | $2.58 | $2K | |
| Linda Burkly - Officer | Open-market sale | Common Stock | 5,121 | $2.49 | $13K | |
| Baisong Mei - Officer | Open-market sale | Common Stock | 541 | $2.08 | $1K | |
| Gilmore Neil O'Neill - Officer | Open-market sale | Common Stock | 1,618 | $2.08 | $3K | |
Recent EDIT Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Burkly Linda | Officer | 700 | $2K | View on EDGAR | |
| O'Neill Gilmore Neil | Officer, Director | 5,100 |
EDIT insider trading FAQ
What is the latest insider trade for EDIT?
Editas Medicine, Inc. (EDIT) had 7 insider filings in the last 90 days, with the most recent on 2026-09-09. The full record for EDIT runs to 30 Form 4 filings, the earliest from 2024-12-05. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying EDIT stock?
No insider purchases of EDIT were filed in the last 90 days.
How many insiders are selling EDIT stock?
5 insider sales of EDIT were filed in the last 90 days, totaling $34K.
Where can I see EDIT SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects EDIT Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Daniel Scott Ory view on EDGAR
- - Linda Burkly view on EDGAR
- - Amy Parison view on EDGAR
- - Gilmore Neil O'Neill view on EDGAR
- - Patrick Thomas Ellinor II view on EDGAR
- - Amy Parison view on EDGAR
- - Linda Burkly view on EDGAR
- - Bernadette Connaughton view on EDGAR
- - Jessica Hopfield view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where EDIT's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow EDIT with a 7-day demo
- EDIT on your watchlist
- Every EDIT Form 4 filing on record
- Up to 3 months of EDIT price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
